Previous studies have suggested that the ancestral haplotype 18.2 (AH18.2) carries additional susceptibility gene to Type 1 Diabetes (T1D) on the Major Histocompatibility Complex (MHC). We analyzed 10 DR3/ TNFa1b5 homozygous subjects in order to establish the conservation of the AH18.2 and then compared this conserved region with other DR3 haplotype, the AH8.1. The Illumina's HumanHap550 Bead chip was used to perform an extensive genotyping of the MHC region.
Introduction Type 1 Diabetes (T1D) is a genetically complex autoimmune disease in which the interaction of genetic and environmental factors causes the selective destruction of pancreatic beta cells. The genetic predisposition to T1D is strongly associated with the MHC chromosomal region, although some genes outside of the MHC class II also contribute to disease risk [1] [2] [3] . In the last few years accumulated evidence suggests that the class II loci cannot explain the entire genetic susceptibility conferred by the MHC for a number of different autoimmune diseases, including Rheumatoid Arthritis (RA) [1] and Multiple Sclerosis (MS) [4] , as well as T1D [1, 3] .
It is generally accepted that the MHC class II loci are likely to be directly involved in diabetes risk, with the highest risk conferred by the haplotypes DR3-DQ2 and DR4-DQ8 [5] [6] [7] . However, several studies have shown that the various DR3-DQ2 haplotypes do not predispose equally to the disease [8] [9] [10] [11] [12] . Two conserved ancestral or extended DR3-DQ2 haplotypes have been associated with diabetes susceptibility [13] : AH8.1 (also known as COX) and AH18.2 (also known as QBL). Both haplotypes carry the same HLA-DR and HLA-DQ alleles but the AH18.2 haplotype confers significantly increased risk compared with other DR3-DQ2 bearing haplotypes, and therefore may carry additional susceptibility genes for T1D [9, 10, 12] . Moreover, no differences exist in diabetes risk between AH8.1 and other DR3-DQ2 haplotypes different from AH18.2 [14] .
Further delineation of the extent of conservation of the AH18.2 haplotype would be useful for narrowing down the possible regions involved in T1D susceptibility. Our first results are presented in this report, using a panel of over 2000 SNPs across the MHC. We aimed at excluding non-conserved regions within this haplotype as carriers of the risk determinant. Obviously, the genetic determinant present in AH18.2 will be shared by the conserved portion of the haplotype. For doing so, 10 homozygous subjects for AH18.2 were compared. For comparison purposes AH18.2 bearers are all useful, regardless their patient/control status.
It is well known that polygenic diseases result from the concurrence of genetic risk factors each rendering a modest increase in susceptibility. Separately, none of them is sufficient/necessary to develop the disease, but a combination is needed to trigger the pathogenic condition. Consequently, healthy subjects may carry a specific susceptibility factor; i.e. around 90% of celiac disease patients carry DQ2 alleles, present as well in healthy controls (up to 20%) [15] .
Results
In DR3 subjects, the TNF microsatellite alleles TNFa1b5 and TNFa2b3 are haplo-specific for AH18.2 and AH8.1 haplotypes respectively, in both Caucasian Spanish and Caucasian American populations [11, 16] . We used these polymorphisms to identify the Supplementary Table 1 ). Haplotypes were reconstructed using fastPHASE and then the 20 haplotypes were compared with the inferred AH18.2 ( Fig. 1 ). The match (blue in Fig. 1) is high between the region centromeric to HLA-A gene and telomeric to HLA-DRB1 gene. The frequency of homozygosity for the consensus AH18.2 allele was near to 1 for SNPs between DDR1 and the HLA-DQA1 genes (HLA-DQA1 is located between HLA-DRB1 and HLA-DQA2, see Fig. 2 ). One of the controls (sample S9, second from the bottom in Fig. 1 ) showed a shorter region of homozygosity likely reflecting a recombination event for this individual.
We also performed the analysis of 20 individuals homozygous for the AH8.1 from the Caucasian U.S. population. As expected, and similarly to the pattern seen for AH18.2, a large fraction of the subjects displayed homozygosity across the entire MHC region (data not shown), emphasizing the extreme haplotypic conservation of the AH8.1, particularly in populations of northern European origin. Since published data suggest that the extended AH18.2 haplotype contains risk alleles for T1D that are not present on the AH8.1, we characterized the differences and similarities of SNP alleles in these haplotypes for all the genes between DDR1 and HLA-DRA (Supplementary Table 2 ). When we grouped by genes the 646 SNPs studied in this region of homozygosity between DDR1 and HLA-DRA, we found 68 genes (Table 1) : 18 located in class I, 48 in class III and only two genes mapped in class II region. Note that 413 SNP alleles within these genes are identical between the two haplotypes, and all the alleles in HLA-DRB1 (6 SNPs) and HLA-DQA1 (11 SNPs) were identical in AH18.2 and AH8.1 haplotypes, as expected (see Supplementary  Table 2 ). In the MHC class III region 16 out of the 48 genes carried the same allele in both AH18.2 and AH8.1 haplotypes for all the SNPs studied. These 16 genes are: ATPase, H+ transporting, lysosomal 13 kDa, V1 subunit G2 (ATP6V1G2), leukocyte specific transcript 1 (LST1), allograft inflammatory factor 1 (AIF1), HLA-B associated transcript 2 and 4 (BAT2 and BAT4), lymphocyte antigen 6 complex, locus G5C and G6D (LY6G5C and LY6G6D) , chromosome 6 open reading frame 27 (C6orf27), heat shock 70 KDa protein 1-like and 1B (HSPA1 and HSPA1B), sialidase 1 (NEU1), solute carrier family 44 member 4 (SLC44A4), complement component 2 (C2), cAMP responsive element binding protein-like 1 ATF6B proline-rich transmembrane protein 1 (PRRT1) and palmitoil-protein thioesterase 2 (PPT2).
The MHC class I region under study comprised of 18 genes between the tyrosine kinase discoidin domain receptor family, member 1 (DDR1) and the highly polymorphic MHC class I chain-related gene B (MICB). All of them presented differences in markers and some have an important role in the immune response: HLA-C, HLA-B and the highly polymorphic MHC class I chain-related gene A and B (MICA and MICB). As well as MHC class I region, the genes found in class II (BTNL2 and HLA-DRA), showed differences in 37% and 50% of the SNPs under study, respectively (Table 1) .
Discussion
We have previously reported that the AH18.2 haplotype confers a higher risk than the AH8.1 haplotype to suffer T1D in our Spanish population [11] . Our criteria in order to select AH18.2 subjects were the presence of DRB1⁎0301 allele and TNFa1b5 haplotype because these TNF alleles are haplo-specific and closer to the HLA-DRB1 gene than the other specific alleles (HLA-B⁎18 and HLA-A⁎30). By screening AH18.2 haplotypes in 10 subjects homozygous for DR3-DQ2 and TNFa1b5, we observed that substantial conservation extends from the DDR1 locus, centromeric to HLA-A, all the way to the HLA-DRA gene in class II region. Thus, it is likely that the specific T1D risk alleles conferred by the AH18.2 haplotype reside in this region. We have further compared the allelic variation between the AH18.2 and AH8.1 haplotypes using our panel of SNPs, and showed that many alleles are shared between these two extended haplotypes. Therefore, these particular alleles cannot be responsible for the increased T1D risk specifically conferred by the AH18.2 haplotype. Of course, this analysis leaves us with a large number of genes and polymorphisms to explore. Some of them are listed in Table 1 , but the overall sequence difference between the AH18.2 and AH8.1 haplotypes is clearly much more extensive than this and, as reported, involves 15,345 SNPs in the MHC region, where near 40% of them were different between both haplotypes [17] .
Even though AH18.2 and AH8.1 haplotypes are generally highly conserved, there is clear evidence of historical meiotic recombination that breaks these large haplotypes up in the population, and these recombinants should be useful for estimating the location of risk genes. By taking a comprehensive approach to the analysis of large populations of T1D cases and controls in the Spanish population, we anticipated that the critical risk region on the AH18.2 haplotype can be further narrowed. The process would be analogous to the analysis using microsatellite markers that was carried out for the AH8.1 haplotype in the context of systemic lupus [18] . The current analysis indicates that such an approach can be applied to the study of the AH18.2 haplotype in populations where this haplotype is common. By microsatellite haplotype mapping using the transmission disequilibrium test (TDT), a 2.35 Mb region between microsatellite D6S2702 (located 970 kb telomeric of HLA-B) and HLA-DOB (centromeric to HLA-DQB2) was delineated as the most likely location for the second risk locus in the AH 18.2 haplotype [8] . The analysis of our data showed that the conserved AH18.2 haplotype does not extend so far away. In our homozygous samples, homozygosity is near 1 between DDR1 and HLA-DQA1 (Fig. 2) . This is, therefore, the region that more probably carries the additional risk gene in T1D patients that present the AH18.2 haplotype. Furthermore, AH18.2 and AH8.1 haplotypes do not differ in their HLA-DRB and HLA-DQ genes composition and when we remove these genes the resulting conserved region comprises only 1.65 Mb, between DDR1 and HLA-DRA loci.
In a recent paper, Nejentsev et al. published compelling evidence that the HLA-B locus itself may confer risk of T1D independent of the HLA-DR or DQ loci. The HLA-B18 present on the 18.2 haplotype was specifically implicated in this study, with a strength of association just below the one shown for the HLA-B39 allele [19] . Indeed, only the B39 and B18 alleles reached statistical significance after conditioning on the class II loci. Thus, it is likely that the HLA-B18 allele explains a substantial proportion of the specific contribution of the 18.2 haplotype to T1D susceptibility, which is in agreement with our data. However, we note that additional signals remained after conditioning on the HLA-B locus, and it is possible that additional alleles on the extended 18.2 haplotype may also contribute to disease risk. On the other hand, our data suggest that the HLA-A allele carried by the 18.2 haplotype is unlikely to contribute to T1D disease risk, since it lies outside the highly conserved region we have defined here. This implies that the HLA-A contributions to disease described by Nejentsev et al. are likely to correspond to other haplotypes. Indeed, the A30 allele found on the AH18.2 haplotype showed no association with T1D, after conditioning on DR, DQ and HLA-B [19] .
In summary, the MHC is recognized as the most important susceptibility region in autoimmune diseases, and provides the largest genetic contribution to T1D risk. The AH18.2 has been often referred to as "diabetogenic haplotype" because it confers significantly increased risk to T1D compared to other haplotypes that carry the same HLA-DRB1 and DQ alleles. This high susceptibility must be due to a gene or genes different from the HLA class II loci and one of these genes appears to be the HLA-B18 allele, as recently described. However, we wish to raise the possibility that there may be additional susceptibility alleles on this haplotype, and candidates can be identified by comparisons with other conserved haplotypes, such as AH8.1. Our study allows us to exclude the regions telomeric to DDR1 and centromeric to HLA-DRA as harboring the additional susceptibility factor.
Materials and methods

Patients and controls
Ten homozygous subjects for DR3 and TNF a1b5 microsatellites: 8 T1D patients (5 female and 3 male) diagnosed according to the criteria of the American Diabetes Association (ADA) and two male controls were recruited from the Hospital Clínico San Carlos, Madrid (Spain). The age at onset for the T1D patients ranges from 1 to 32 years old and all of them were insulin-dependent at the time of the study.
Twenty healthy Caucasian controls (11 female and 9 male) homozygous for DR3 and TNF a2b3 were included in this study. They were collected from the New York Cancer Project (NYCP) and were cancer-free at the time of enrollment.
Genotyping
All samples were genotyped for HLA-DRB1 alleles [20, 21] and for 2 microsatellite markers (TNFa and TNFb) [22] as previously described.
Microsatellite alleles were ascertained using an ABI Prism 3100 automatic sequencer (Applied Biosystems, Foster City, CA, USA).
The genome-wide scan was carried out using the Illumina's HumanHap550 Bead chip.
Statistical analysis
The call rate clean up was performed with Genetics Analysis Software HelixTree ® (© 2007 Golden Helix Inc.) version 5.3.1 (http:// www.goldenhelix.com).
The two haplotypes of each individual are reconstructed from the genotype data using the fastPHASE program (http://stephenslab. uchicago.edu/software.html).
To produce the plots we have used R statistical package (http:// www.r-project.org/).
